It has also been suggested that MET reduces hepatic TG accumulation and improves obesity-related NAFLD by inhibiting hepatic apolipoprotein A5 (ApoA5) synthesis through the AMPK/LXRα signaling pathway [101]. This evidence concerns the gene APOA5 and obesity disorder.